# Safety and Tolerability of BI 685509 in Healthy Subjects

> **NCT03116906** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 60 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BI 685509
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03116906
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-24
- **Primary completion:** 2018-06-01
- **Final completion:** 2018-06-01
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2018-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03116906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03116906, "Safety and Tolerability of BI 685509 in Healthy Subjects". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03116906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*